Dr. David Cheishvili is Chief Innovation Officer at epiMedTech Global, affiliated with the Department of Oncology at McGill University in Montreal, and also holds leadership roles at NanoWellness Inc. and MTL Epitherapeutics Inc. Dr. David Cheishvili holds a PhD in Biochemistry and Molecular Biology from The Hebrew University. He is a molecular biologist and epigenetics researcher with over 25 years of experience spanning academia, clinical trials, and biotech innovation. He has co-invented patents in cancer detection and epigenetic age testing, led clinical trials and research in epigenetics, and published extensively on DNA methylation and diagnostics.